DMP — Dermapharm Holding SE Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Dermapharm Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	794	943	1,025	1,135	1,181
Cost of Revenue
Gross Profit	463	621	661	719	767
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	657	644	781	952	964
Operating Profit	137	298	244	183	217
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	125	293	216	106	172
Provision for Income Taxes
Net Income After Taxes	85.9	209	133	60.5	112
Minority Interest
Net Income Before Extraordinary Items
Net Income	85.8	210	134	62.4	114
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	85.8	210	134	62.4	114
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.86	4.19	3.27	1.66	2.31
Dividends per Share